W. R. Berkley
WRB
$68.96
+2.71%
W.R. Berkley Corporation is an insurance holding company that primarily underwrites commercial casualty insurance through a host of subsidiaries. The firm operates as a specialist in niche markets, focusing on excess and surplus lines, workers' compensation, reinsurance, and regional commercial lines for small to midsize businesses. The current investor narrative centers on the company's ability to navigate a hardening insurance market, with attention on its disciplined underwriting and capital allocation as it seeks to deliver consistent profitability amidst industry-wide pricing and loss cost pressures. Recent financial trends and news highlight ongoing debates about the sustainability of its premium growth and margin trajectory in the face of potential economic headwinds.…
WRB
W. R. Berkley
$68.96
Related headlines
Investment Opinion: Should I buy WRB Today?
Rating & Thesis: Hold. WRB is a financially sound insurer trading at a reasonable valuation, but it is trapped in a persistent downtrend with deteriorating profitability, making it premature to recommend a Buy despite its defensive attributes. The mixed analyst sentiment, with recent downgrades offsetting a few Buy ratings, supports a cautious, wait-and-see stance.
Supporting Evidence: The Hold rating is supported by four key data points: 1) A reasonable forward P/E of 13.95x, which is below the trailing multiple and suggests some earnings growth is priced in; 2) A strong balance sheet with a debt-to-equity ratio of 0.29 and a current ratio of 1.39; 3) Exceptional free cash flow generation of $3.43 billion TTM, providing a margin of safety; and 4) A dividend yield of 2.52%, offering income while investors await a turnaround. However, these are counterbalanced by the 22% YoY decline in Q4 net income and the stock's significant underperformance.
Risks & Conditions: The two biggest risks are the continuation of margin erosion and a failure to break the technical downtrend. This Hold rating would upgrade to a Buy if the company demonstrates a clear quarter of sequential margin improvement or if the stock sustains a break above the $71-$73 resistance zone on strong volume. It would downgrade to a Sell if Q4 profitability compression accelerates or if the stock decisively breaks below the $62.87 support level. Relative to its own history, the stock appears fairly valued, but it is not demonstrably cheap enough to outweigh the clear negative momentum.
Sign up to view all
WRB 12-Month Price Forecast
The AI assessment is neutral with medium confidence. WRB presents a classic value versus momentum conflict. Its strong fundamentals—low debt, robust FCF, and reasonable valuation—are compelling, but they are being overwhelmingly discounted by the market due to negative earnings momentum and poor price action. The stance would upgrade to bullish on concrete evidence of margin stabilization (e.g., two consecutive quarters of flat or improving net margin). It would turn bearish if the next earnings report shows an acceleration in the profitability decline, confirming the negative trend is entrenched rather than transitory.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on W. R. Berkley's 12-month outlook, with a consensus price target around $89.65 and implied upside of +30.0% versus the current price.
Average Target
$89.65
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$55 - $90
Analyst target range
Analyst coverage for WRB appears limited, with only 3 analysts providing estimates for future EPS and revenue, and no explicit consensus price target, buy/hold/sell distribution, or target range provided in the data. The institutional ratings data shows recent activity from several firms, including maintains of 'Buy' or 'Overweight' ratings from Argus Research and Cantor Fitzgerald, alongside maintains of 'Neutral' or 'Hold' from B of A Securities, Mizuho, Jefferies, and Wells Fargo. Notably, TD Cowen downgraded the stock to 'Sell' from 'Hold' in January 2026. This pattern suggests a mixed but generally cautious sentiment among covering analysts, with no strong consensus bullish push. The lack of a broad analyst target dataset typically indicates the stock is a mid-cap name with steady but not high-growth prospects, leading to lower institutional research coverage, which can contribute to the stock's lower beta and relative underperformance versus the broader market.
Bulls vs Bears: WRB Investment Factors
The evidence presents a balanced but challenging picture for WRB. The bear case currently holds stronger evidence, primarily driven by the stock's severe technical underperformance, clear year-over-year earnings decline, and stagnant revenue growth, which collectively overshadow its financial strengths. The most critical tension in the investment debate is whether the company's robust free cash flow generation and defensive balance sheet can offset the deteriorating profitability trend and reignite investor confidence. The resolution of this tension—specifically, a stabilization or reversal of the margin compression—will determine if the stock transitions from a value trap to a value opportunity.
Bullish
- Strong Free Cash Flow Generation: The company generated $3.43 billion in TTM free cash flow, providing significant financial flexibility. This robust cash generation supports consistent dividends, share repurchases, and organic growth without reliance on debt, as evidenced by a low debt-to-equity ratio of 0.29.
- Attractive Valuation Relative to Earnings: WRB trades at a forward P/E of 13.95x, below its trailing P/E of 15.63x, indicating the market expects earnings growth. This valuation is in the middle of its recent historical range, suggesting it is not overextended and offers a reasonable entry point for a profitable insurer.
- Solid Balance Sheet and Low Volatility: A current ratio of 1.39 and a market beta of 0.311 indicate strong liquidity and significantly lower volatility than the broader market. This defensive profile makes the stock less susceptible to market-wide sell-offs, offering downside protection in turbulent times.
- Disciplined Underwriting in Niche Markets: As a specialist in commercial casualty and excess/surplus lines, WRB operates in less competitive, higher-margin niches. This focus, combined with a Q4 2025 operating margin of 16.31%, demonstrates its ability to maintain profitability through disciplined risk selection.
Bearish
- Persistent Underperformance and Downtrend: The stock has underperformed the S&P 500 by 32.68% over the past year and is down 7.69% Y/Y. Trading just 16% above its 52-week low of $62.87, the price action reflects sustained negative momentum and investor skepticism about near-term catalysts.
- Year-Over-Year Profitability Compression: Q4 2025 net income of $449.5 million represents a 22% decline from $576.1 million in Q4 2024, with the net margin compressing from 15.7% to 12.1%. This trend raises concerns about the sustainability of earnings power amidst rising loss costs or competitive pressures.
- Stagnant Revenue Growth Trajectory: Q4 2025 revenue grew only 1.4% year-over-year, and quarterly revenue has fluctuated between $3.55B and $3.77B throughout 2025. This lack of accelerating top-line expansion limits the potential for multiple expansion and suggests market saturation in its core segments.
- Mixed-to-Cautious Analyst Sentiment: Recent analyst activity includes a downgrade to 'Sell' by TD Cowen and multiple 'Hold' or 'Neutral' ratings from major firms. The limited coverage (only 3 analysts providing estimates) and lack of a strong bullish consensus indicate institutional wariness about the stock's near-term prospects.
WRB Technical Analysis
The stock is in a sustained downtrend, evidenced by a 1-year price change of -7.69%, significantly underperforming the S&P 500's 24.99% gain. Currently trading at a price of $67.18, it sits near the lower end of its 52-week range of $62.87 to $78.96, positioning it at approximately 16% above its 52-week low. This proximity to the low suggests the stock is in a value-seeking zone but also reflects persistent negative momentum and investor skepticism. Recent momentum shows a short-term bounce, with a 3-month price change of 2.19%, yet this is overshadowed by a 1-month decline of -1.96%, indicating the recovery is fragile and the longer-term downtrend remains dominant. The stock's beta of 0.311 indicates it is significantly less volatile than the broader market, which, while reducing downside risk during market stress, also suggests limited participation in broader market rallies. Key technical support is clearly defined at the 52-week low of $62.87, while resistance lies at the 52-week high of $78.96. A decisive break below support would signal a continuation of the bearish trend, whereas a sustained move above the $71-$73 range (recent highs from February-March) is needed to suggest a meaningful reversal is underway.
Beta
0.31
0.31x market volatility
Max Drawdown
-19.0%
Largest decline past year
52-Week Range
$63-$79
Price range past year
Annual Return
-6.7%
Cumulative gain past year
| Period | WRB Return | S&P 500 |
|---|---|---|
| 1m | +2.1% | -1.6% |
| 3m | +6.9% | +11.7% |
| 6m | -2.4% | +6.3% |
| 1y | -6.7% | +22.2% |
| ytd | -0.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRB Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $3.72 billion representing a year-over-year increase of 1.4%. However, examining the quarterly sequence from Q1 to Q4 2025 shows revenue fluctuating between $3.55 billion and $3.77 billion, indicating stable but not accelerating top-line expansion. The Insurance-Domestic Segment, at $3.04 billion, is the primary revenue driver, significantly larger than the Reinsurance-Global Segment's $455 million. The company is profitable, with Q4 2025 net income of $449.5 million and a net margin of 12.1%. Gross margin for the quarter was 20.58%, and the operating margin was 16.31%. Comparing to the prior-year Q4, net income of $576.1 million and a net margin of 15.7% reveals a year-over-year compression in profitability, a key point for analysis. The balance sheet and cash flow position are strong, with a low debt-to-equity ratio of 0.29 and a robust current ratio of 1.39. The company generated substantial free cash flow of $896.2 million in Q4 2025 and has a trailing twelve-month free cash flow of $3.43 billion, providing ample internal capital to fund operations, dividends, and share repurchases without reliance on external financing.
Quarterly Revenue
$3.7B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.20%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRB Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 15.63x, while the forward PE is lower at 13.95x, indicating the market expects earnings growth. The gap suggests the market is pricing in an improvement in profitability from current levels. Compared to its own historical range, the current trailing PE of 15.63x is below the higher end of its recent historical band (e.g., 18.17x in Q2 2025) but above the lows seen in late 2024 (around 10.1x to 12.1x). This positions the valuation in the middle of its recent historical range, suggesting it is neither excessively cheap nor expensive based on its own history, but rather reflecting a market that is cautiously optimistic about a earnings recovery. The stock trades at a Price-to-Sales ratio of 1.89x and a Price-to-Book ratio of 2.87x, which are reasonable for a profitable, established P&C insurer, though direct industry average comparisons from the provided data are not available for a precise premium/discount calculation.
PE
15.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the clear compression in profitability, with net income declining 22% year-over-year in Q4 2025 and the net margin falling 360 basis points. While revenue growth is stable at 1.4% YoY, this lack of acceleration, combined with margin pressure, suggests the company may be struggling to pass on rising loss costs or is facing increased competition in its niche markets. The high PEG ratio of 7.63 further indicates the market is pricing in significant future growth that may not materialize if these trends persist, posing a valuation risk.
Market & Competitive Risks: The stock trades at a forward P/E of 13.95x, which is reasonable historically but faces compression risk if earnings continue to disappoint. Its low beta of 0.311, while defensive, also means it has failed to participate in the broader market rally, underperforming the S&P 500 by over 32% in the past year. This suggests a sector-specific headwind or a negative company narrative that is outweighing its defensive characteristics. Competitive risks are highlighted by news of peers like Palomar pursuing aggressive growth strategies, potentially encroaching on WRB's specialty markets.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, triggered by another quarter of declining year-over-year earnings and margin compression. This could lead to further analyst downgrades and a loss of investor patience, driving the stock to re-test and break its 52-week low of $62.87. Given the stock's 19.02% maximum drawdown and current price of $67.18, a realistic downside scenario could see a decline of approximately 6.4% to the 52-week low. A more severe bear case, factoring in multiple compression on lowered earnings estimates, could push the stock toward the $60 level, representing a potential loss of 10-15% from current levels.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The 22% YoY decline in Q4 net income may continue if underwriting margins keep compressing. 2) Sentiment & Momentum Risk: The stock has underperformed the S&P 500 by over 32% in the past year, and negative price momentum can become self-fulfilling. 3) Growth Risk: Stagnant revenue growth (~1.4% YoY) limits upside potential and could lead to multiple compression. 4) Analyst Risk: The recent downgrade to 'Sell' and generally cautious coverage could limit institutional buying interest.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $67 and $72, as current challenges persist without major deterioration. The Bull Case (25% probability) targets $75 to $79, driven by a margin recovery and renewed investor confidence. The Bear Case (15% probability) warns of a drop to $60-$63 if profitability worsens. The Base Case is most likely, predicated on the assumption that the company's strong free cash flow and balance sheet prevent a collapse, but lacking a catalyst for a sharp recovery.
WRB appears fairly valued relative to its own recent history. Its trailing P/E of 15.63x is in the middle of its historical range, and the forward P/E of 13.95x suggests the market is pricing in modest earnings improvement. The Price-to-Book of 2.87x and Price-to-Sales of 1.89x are reasonable for a profitable P&C insurer. The valuation is not demanding, but it also does not scream 'cheap' given the clear downward trend in profitability. The market is paying a fair price for a company whose near-term earnings power is in question.
WRB is a conditional buy, suitable only for patient, value-oriented investors comfortable with near-term uncertainty. The stock offers a reasonable forward P/E of 13.95x, a strong 2.5% dividend, and an exceptionally robust balance sheet. However, its 22% year-over-year decline in Q4 net income and severe underperformance versus the market are significant red flags. It could be a good buy for those betting on a profitability turnaround, but investors seeking growth or momentum should look elsewhere.
WRB is unsuitable for short-term trading due to its low beta (0.311) and lack of positive momentum. It is best considered a long-term investment with a minimum horizon of 2-3 years. This allows time for the company to potentially navigate the current profitability headwinds, for its capital return program (dividends/buybacks) to compound, and for the valuation gap to close. The 2.5% dividend yield also supports a total-return approach for long-term holders, providing income while waiting for capital appreciation.